A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE4
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
- Status
- TERMINATED
- Phase
- PHASE2
Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.
- Status
- COMPLETED
- Phase
- PHASE1
Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE2
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study to Nivolumab Following Preoperative Chemoradiotherapy
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2